Evidence map›Paper›PMID 24473329›Full record

ArticleThorax2014

Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.

Michelle C Williams, John T Murchison, Lisa D Edwards, Alvar Agustí, Per Bakke, Peter M A Calverley, Bartolome Celli, Harvey O Coxson, Courtney Crim, David A Lomas and 11 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Thorax, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03285100 (Pilot Study to Assess the Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation), which is not on this map. Cited by 100 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 3 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03285100 unknown statusnot on this mapstarted 2017, after this paper: background citation

Pilot Study to Assess the Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation

TypeobservationalSponsorCanisius-Wilhelmina HospitalRan2017 to 2018Enrolled30ConditionsEmphysema or COPD, Aneurysm, Cystic Fibrosis, Alpha 1-Antitrypsin DeficiencyArmsVenipuncture
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 8 countries.

Michelle C WilliamsUniversity of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK.
John T MurchisonRoyal Infirmary of Edinburgh, Edinburgh, UK.
Lisa D EdwardsGlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Alvar AgustíThorax Institute, Hospital Clinic, Universitat de Barcelona; CIBER Enfermedades Respiratorias (CIBERES), FISIB, Mallorca, Spain.
Per BakkeUniversity of Bergen, Bergen, Norway.
Peter M A CalverleyDepartment of Respiratory Medicine, University Hospital Aintree, Liverpool, UK.
Bartolome CelliDepartment of Respiratory Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Harvey O CoxsonUniversity of British Columbia, Vancouver, British Columbia, Canada.
Courtney CrimGlaxoSmithKline, Research Triangle Park, North Carolina, USA.
David A LomasDepartment of Medicine, University of Cambridge, Cambridge, UK.
Bruce E MillerGlaxoSmithKline, King of Prussia, Pennsylvania, USA.
Steve RennardUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Edwin K SilvermanDepartment of Respiratory Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Ruth Tal-SingerGlaxoSmithKline, King of Prussia, Pennsylvania, USA.
Jørgen VestboDepartment of Respiratory Medicine, Odense University & University of Southern Denmark, Denmark/University of Manchester, Academic Health Science Centre, Manchester, UK.
Emiel WoutersDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
Julie C YatesGlaxoSmithKline, King of Prussia, Pennsylvania, USA.
Edwin J R van BeekClinical Research Imaging Centre, University of Edinburgh, Edinburgh, UK.
David E NewbyUniversity of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK.
William MacNeeCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators
GlaxoSmithKline (United States) · USUniversity of Edinburgh · GBResearch Triangle Park Foundation · USBrigham and Women's Hospital · USBritish Heart Foundation · GBCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESEdinburgh Royal Infirmary · GBHarvard University · USMaastricht University Medical Centre · NLUniversity of Bergen · NOUniversity of British Columbia · CAUniversity of Cambridge · GBUniversity of Liverpool · GBUniversity of Manchester · GBUniversity of Nebraska Medical Center · US

Funding

British Heart Foundation CH/09/002British Heart Foundation FS/11/14/28692British Heart Foundation RE/08/001Medical Research Council G0701127Medical Research Council G0901786
6 · The paper itself

Abstract

backgroundCoronary artery calcification is pathognomonic of coronary artery disease (CAD). Whether CAD in patients with COPD is linked to lung function, functional capacity and/or clinically relevant outcomes is unknown. The objective was to assess the association between CAD and disease severity, functional capacity and outcomes in patients with COPD.

methodsCoronary artery calcium score (CACS; Agatston score) was measured using chest CT in patients with COPD, smokers with normal spirometry and non-smokers from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study.

resultsCACS was measured in 942 subjects: 672 with COPD (mean age±SD, 63±7 years; FEV1 49±16% predicted), 199 smokers with normal spirometry (54±9 years; FEV1 110±12% predicted) and 71 non-smokers (55±9 years; FEV1 114±14% predicted). CACS was higher in patients with COPD than smokers or non-smokers (median (IQR), 128 (492) vs 0 (75) vs 0 (3) Agatston units (AU), p<0.001). In patients with COPD, CACS correlated with age, pack-years, 6 min walking distance, modified Medical Research Council Dyspnoea score and circulating levels of interleukin (IL)-6, IL-8, Clara Cell protein 16, surfactant protein D and peripheral blood neutrophil count, but not with emphysema, exacerbation frequency, % predicted FEV1 or decline in FEV1. CACS was higher in patients with COPD who died than in those who survived until 3-year follow-up (CACS 406 vs 103 AU, p<0.001), and was associated with mortality in a Cox proportional hazards model (p=0.036).

conclusionsPatients with COPD have more CAD than controls and this is associated with increased dyspnoea, reduced exercise capacity and increased mortality. These data indicate that the presence of CAD in patients with COPD is associated with poor clinical outcomes.

Indexed as

AdultAgedBiomarkersCalcinosisCoronary Artery DiseaseDyspneaFemaleHumansLongitudinal StudiesMaleMiddle AgedPhenotypePhysical EndurancePredictive Value of TestsPulmonary Disease, Chronic ObstructiveRespiratory Function TestsBiomarkersCOPD ÀÜ MechanismsEmphysemaImaging/CT MRI etc

Identifiers

PMID24473329
OpenAlexW2161987121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.